glargine and humalog — Competitive Intelligence Brief

glargine and humalog (glargine and humalog) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin analog combination (basal-bolus therapy). Area: Diabetes.

marketed Insulin analog combination (basal-bolus therapy) Insulin receptor Diabetes Small molecule

Target snapshot

glargine and humalog (glargine and humalog) — Riverside University Health System Medical Center. Glargine is a long-acting basal insulin that provides steady glucose control, while Humalog is a rapid-acting insulin that covers mealtime glucose spikes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
glargine and humalog TARGET	glargine and humalog	Riverside University Health System Medical Center	marketed	Insulin analog combination (basal-bolus therapy)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin analog combination (basal-bolus therapy) class)

1. Riverside University Health System Medical Center · 1 drug in this class